Fortress Biotech, Inc.
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
About Fortress Biotech
Pharmaceutical Preparations, SIC 2834
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical assets and product candidates. The company operates primarily through public partner companies and private subsidiaries, which collaborate with academic institutions and pharmaceutical partners. Its commercial offerings focus on branded dermatology therapies, including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, and other topical treatments for conditions such as rosacea, severe acne, and primary axillary hyperhidrosis. Fortress also advances a clinical and preclinical pipeline spanning oncology, viral infections, rare pediatric genetic disorders, and acute pain.
The company conducts its development and commercialization activities primarily in the United States, alongside global research partnerships, licensing arrangements, and multicenter clinical trials. Its commercial dermatology portfolio is marketed for sale within the United States. Fortress does not disclose specific facility counts or a corporate headquarters location in the provided text.
Summary of the business section of Fortress Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Fortress Biotech, Inc.
- Founded
- 2006
- Headquarters
- Bay Harbor Islands, FL
- Address
- 1111 Kane Concourse, Suite 301 33154
- Phone
- (781) 652-4500
- Website
- www.fortressbiotech.com
- Employees
- 78, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- FBIO
- Other tickers
- FBIOP
- Exchange
- Nasdaq
- IPO date
- Jun 22, 2012
- Shares outstanding
- 37M, Aug 10, 2026
- Public float
- $43.74M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Oct 10, 2023; 1-for-15 reverse, Aug 10, 2023
- SEC CIK
- 1429260
- CUSIP
- 34960Q307
- ISIN
- US34960Q3074
- LEI
- 529900DZUWSYUURECK24
- EIN
- 20-5157386
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael S. Weiss | Executive Vice Chairman, Director | 2,276,562 |
| Lindsay A. Rosenwald Md | PRESIDENT, CEO & CHAIRMAN, Director | 6,954,507 |
| David Jin | Chief Financial Officer | 1,651,571 |
| J. Jay Lobell | Director | 192,397 |
| Jimmie Harvey | Director | 146,704 |
| Dov Klein | Director | 131,905 |
| Kevin Lorenz | Director | 101,675 |
| Malcolm Hoenlein | Director | 115,747 |
| Lucy Lu | Director | 61,273 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Year | $2.89M | $3.56M | $1.55M | – | – |
| FY2024 Year | $1.38M | $807.50K | $1.90M | $5 | – |
| FY2023 Year | $1.12M | -$1.90M | $1.22M | $8 | – |
| FY2022 Dr. Rosenwald | $1.27M | -$8.74M | $1.37M | $26 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 78 full-time employees at Fortress and our subsidiaries and partner companies.”
Corporate history
Events identified from SEC filings